Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06460324 · ClinicalTrials.gov registry record
A Study to Assess COVID-19 Vaccination Immune Response in Multiple Sclerosis Patients Treated With Ofatumumab
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 38
- Enrollment target
NCT06460324 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 38 participants.
The verdict
NCT06460324 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 38 participants
- Enrollment target
Study Summary
This was a non-interventional, retrospective, observational cohort study involving the abstraction and review of pertinent data from medical records by participating physicians, who completed a customized electronic case report form hosted on the secure electronic data capture system.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2022-05-20 |
| Est. Completion | 2023-07-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06460324
The ClinicalTrials.gov registry entry for NCT06460324 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT06460324 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06460324 about?
NCT06460324 is a clinical study titled "A Study to Assess COVID-19 Vaccination Immune Response in Multiple Sclerosis Patients Treated With Ofatumumab". This was a non-interventional, retrospective, observational cohort study involving the abstraction and review of pertinent data from medical records by participating physicians, who completed a customized electronic case report form hosted on the secure electronic data capture system.
What is the current status of trial NCT06460324?
This trial is currently completed. The enrollment target is 38 participants. The study started on 2022-05-20. Estimated completion is 2023-07-03.
Who is sponsoring clinical trial NCT06460324?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.